Literature DB >> 3302764

[Buprenorphine in cancer pain: cross comparison with pentazocine].

F De Conno, C Ripamonti, M Tamburini, V Ventafridda.   

Abstract

In a randomized cross-study analgesic activity and side effects of two narcotics, buprenorphine and pentazocine, administered orally in 91 advanced cancer patients whose pain intensity varied from moderate to severe, have been compared. The number of hours of sleep and hours standing after administration of both the drugs were also assessed and in 16 patients life activity was taken into consideration. The analysis of data showed: a better pain control with buprenorphine, than with pentazocine, with a statistically significant difference of P less than 0.001; an increase in the number of hours of sleep with buprenorphine, in comparison with pentazocine, with P less than 0.001; an increase in the number of hours standing with buprenorphine, in comparison with pentazocine; as for side effects, many more patients had to stop treatment with pentazocine than with buprenorphine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3302764

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  3 in total

Review 1.  Buprenorphine for treating cancer pain.

Authors:  Mia Schmidt-Hansen; Nathan Bromham; Mark Taubert; Stephanie Arnold; Jennifer S Hilgart
Journal:  Cochrane Database Syst Rev       Date:  2015-03-31

Review 2.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

Review 3.  A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain.

Authors:  Cho Naing; Peng Nam Yeoh; Kyan Aung
Journal:  Springerplus       Date:  2014-02-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.